profit from every $100 of sales.
$0$100
Accuray
$3.82+3,372.73% today
+226.5% in 1 year
1-year low $0.111-year high $3.82
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Accuray sold, what it kept, and what it did with the cash.
Sales went from $430 million in 2022 to $459 million in 2025, with -$1.59 million of profit last year.
SalesProfit
Accuray vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Accuray | No profit yet | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads Accuray's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 430 | 448 | 447 | 459 | |
| 160 | 154 | 143 | 147 | |
| 8 | 2 | 1 | 8 | |
| 12 | 8 | 6 | 20 | |
| -5 | -9 | -16 | -2 | |
| -0.06 | -0.10 | -0.16 | -0.02 | |
| 37.2% | 34.4% | 32.0% | 32.1% | |
| 1.9% | 0.5% | 0.1% | 1.7% | |
| -1.2% | -2.1% | -3.5% | -0.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 473 | 479 | 469 | 470 |
| Cash | 89 | 89 | 69 | 57 |
| Total debt | 199 | 205 | 211 | 176 |
| Total liabilities | 420 | 426 | 424 | 389 |
| 53 | 54 | 45 | 81 | |
| 92 | 95 | 98 | 103 | |
| 1.9% | 1.2% | -0.1% | 4.3% | |
| -10.1% | -17.3% | -34.5% | -2.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -2 | 16 | -12 | 3 | |
| 5 | 13 | 4 | 9 | |
| -7 | 3 | -16 | -6 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 11 | 10 | 9 | 10 |
Valuation
- –
- –
- –
- 0.8×
- 0.0×
- –
- 6.4×
- -49.4%
- -13.9%
- 0.0%
Profitability
- 32.1%
- 1.7%
- -0.3%
- -1.5%
- -5.8%
- -3.0%
- -77.5%
- -10.3%
- -6.3%
- 9.7%
Growth
- +2.2%
- –
- +63.5%
- –
- +2.8%
Financial health
- 5.9×
- 4.37
- 40.7%
- -0.5×
- 1.42
- 0.66
- 0.96
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 31%of 948
Bottom 32%of 871
Bottom 20%of 868
Bottom 1%of 985
What analysts expect
- Average price target
- $2.00
- Range
- $2.00 – $2.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.09 | -0.05 | −80.0% |
| Feb 4, 2026 | -0.11 | -0.11 | −2.2% |
| Nov 5, 2025 | -0.18 | -0.01 | −1,700.0% |
| Aug 13, 2025 | 0.01 | 0.03 | −65.6% |
| Apr 30, 2025 | -0.01 | -0.05 | +80.0% |
| Feb 5, 2025 | 0.02 | -0.01 | +300.0% |
| Nov 6, 2024 | -0.04 | -0.03 | −24.5% |
| Aug 14, 2024 | 0.03 | 0.04 | −25.0% |
News
Accuray expects $15M of incremental annualized cost and margin improvement in FY27 while withholding formal revenue and adjusted EBITDA guidanceSeeking Alpha · Aug 19, 2026The newest story we have is from Aug 19, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
19No pass
Benjamin Graham
37No pass
Philip Fisher
20No pass
Peter Lynch
9No pass
Joel Greenblatt
33No pass
Charlie Munger
13No pass
Terry Smith
18No pass
Questions about Accuray
Is Accuray a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Accuray AI analysis
What does Accuray do?
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It is in Medical - Devices.
Does Accuray pay a dividend?
No. Accuray does not pay a dividend at the moment.
Is Accuray stock halal?
No. Accuray does not pass our halal screen: its debt is 1,539% of its market value, at or above the 33% limit. How we check
How has Accuray stock done over the past year?
Up 226.5% over the past twelve months, to $3.82. It traded between $0.11 and $3.82, close to its high.
Who are Accuray's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Accuray's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.